Pacira Biosciences Inc
F:82P

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
F:82P
Watchlist
Price: 22 EUR 1.85%
Market Cap: 1B EUR

Wall Street
Price Targets

82P Price Targets Summary
Pacira Biosciences Inc

Wall Street analysts forecast 82P stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 82P is 30.1 EUR with a low forecast of 20.72 EUR and a high forecast of 53.86 EUR.

Lowest
Price Target
20.72 EUR
6% Downside
Average
Price Target
30.1 EUR
37% Upside
Highest
Price Target
53.86 EUR
145% Upside
Pacira Biosciences Inc Competitors:
Price Targets
AETHER
Aether Industries Ltd
25% Upside
NATCOPHARM
Natco Pharma Ltd
1% Upside
COPN
Cosmo Pharmaceuticals NV
9% Upside
HIKAL
Hikal Ltd
28% Upside

Revenue
Forecast

Revenue Estimate
Pacira Biosciences Inc

For the last 13 years the compound annual growth rate for Pacira Biosciences Inc's revenue is 34%. The projected CAGR for the next 4 years is 7%.

34%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Pacira Biosciences Inc

The compound annual growth rate of Pacira Biosciences Inc's operating income for the next 4 years is 25%.

N/A
Past Growth
25%
Estimated Growth
Estimates Accuracy
-50%
Average Miss

Net Income
Forecast

Net Income Estimate
Pacira Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-60%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 82P's stock price target?
Price Target
30.1 EUR

According to Wall Street analysts, the average 1-year price target for 82P is 30.1 EUR with a low forecast of 20.72 EUR and a high forecast of 53.86 EUR.

What is Pacira Biosciences Inc's Revenue forecast?
Projected CAGR
7%

For the last 13 years the compound annual growth rate for Pacira Biosciences Inc's revenue is 34%. The projected CAGR for the next 4 years is 7%.

What is Pacira Biosciences Inc's Operating Income forecast?
Projected CAGR
25%

The compound annual growth rate of Pacira Biosciences Inc's operating income for the next 4 years is 25%.

Back to Top